PREVENT Cardiovascular Risk Calculator (AHA/ACC 2023)
AHA/ACC 2023 PREVENT equations predict 10- and 30-year risk of total cardiovascular disease (CVD) events including heart failure. Replaces pooled cohort equations. Validated across diverse populations.
Score interpretation
10-year CVD risk <5%. Low risk population.
→ Lifestyle optimisation. Primary prevention counselling. Reassess in 4-6 years. Statins generally not indicated.
10-year CVD risk 5-9.9%. Borderline risk.
→ Risk discussion with shared decision-making. Consider risk-enhancing factors. Moderate-intensity statin if risk-enhancing factors present.
10-year CVD risk 10-19.9%. Intermediate risk.
→ Statin therapy recommended. LDL target < 2.6 mmol/L. Lifestyle intensification. Consider CAC score to guide further.
10-year CVD risk >=20%. High risk.
→ High-intensity statin. LDL target < 1.8 mmol/L. Aspirin consideration. Aggressive risk factor modification. Cardiology referral.
Interpretation bands for the PREVENT Score. Apply clinical judgement and local guidance.
References
- Khan SS, et al. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol. 2018;3(4):280-287.
- Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350.
Related
Curated clinical cross-links plus same-class fallbacks.
- Framingham Risk Score · Cardiovascular Risk
- ACC/AHA Pooled Cohort Equations — ASCVD Risk · Cardiovascular Risk
- Reynolds Risk Score for Women · Cardiovascular Risk
- SCORE2 — 10-Year CVD Risk (Age 40–69) · Cardiovascular Risk
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
- SCORE2-Diabetes 10-Year CVD Risk in Type 2 Diabetes · Cardiovascular Risk
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Fluvastatin · HMG-CoA reductase inhibitor (statin)
- Pravastatin sodium · HMG-CoA reductase inhibitor (hydrophilic statin)
- Tenecteplase · Cardiovascular Emergency
- Tirofiban · Cardiovascular Emergency
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.